Not every patient reacts to a medicine in the same way. The personal genetic characteristics of individuals and populations can explain why a specific prescription successfully treats one patient and not another.
The path to a functionally active recombinant pharmaceutical can be plagued with technical pitfalls and failures. Strategies can optimize use of time and resources.
Bioo Scientific has expanded its line of kits for next generation sequencing sample preparation with the introduction of the AIR Genomic and AIR Paired-End DNA Sequencing Kits, designed for use with the llumina GAII and HiSeq 2000 sequencers.
Thermo Fisher Scientific Inc. has announced the Thermo Scientific Prima PRO, a next-generation process massspectrometer for online gas analysis in biotechnology applications.
Ricerca Biosciences, a preclinical contract research organization (CRO) providing services to the biopharmaceutical industry, has announced the addition of Eric J. Lubert, Ph.D., as a scientist in its drug safety division.
GlaxoSmithKline R&D announced the start of four new academic collaborations with Singapore-based scientists and GSK’s global drug discovery network as the first step in a longer term plan to seek alliances with scientific experts in the country.
Researchers in India have demonstrated that producing nanoscopic crystals of a pharmaceutical product can allow the medication to be absorbed by the gut even if the drug is not soluble in water.
While human cells have 23 pairs of chromosomes, tumor cells usually have extra copies of some chromosomes. This trait, known as aneuploidy, appears to give tumor cells a survival edge.
The Food and Drug Administration must update its scientific tools for reviewing prescription drugs, medical devices and tracking food safety, according to a research plan laid out by agency leadership.
Revenue from global prescription drug sales should increase 5 percent to 7 percent next year, reaching at least $880 billion, fueled by new drugs and rising sales in developing countries, according to drug data firm IMS Health.
The monoclonal antibody rituximab given in addition to a standard chemotherapy regimen of fludarabine plus cyclophosphamide significantly prolongs the lives of patients with chronic lymphocytic leukaemia compared with standard chemotherapy alone.
The data demonstrated that Jevtana with prednisone reduced the risk of death by 30% in men with metastatic castration-resistant prostate cancer whose disease progressed following treatment with a docetaxel-containing treatment regimen.
Amgen announced that results from the PRIME '203' and '181' pivotal Phase 3 trials evaluating Vectibix in combination with chemotherapy (FOLFOX or FOLFIRI) as a first and second-line treatment for metastatic colorectal cancer, respectively.
ISTA Pharmaceuticals, Inc. announced positive preliminary results from a Phase 1/2 clinical study of bepotastine besilate nasal spray for the treatment of symptoms associated with seasonal allergic rhinitis, the inflammation of the nasal passages caused by allergies.
Researchers at Immunocore Limited announced that IMCgp100, a targeted therapeutic for the treatment of advanced metastatic melanoma, has received regulatory and ethics approval and has opened enrollment for clinical trials in the UK and USA.